Evidence map›Paper›PMID 41792115›Full record

ArticleBlood cancer journal2026

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Niccolò Bartalucci, Francesco Mannelli, Danilo Tarantino, Alessio Enderti, Simone Romagnoli, Daniele Colazzo, Barbara Scappini, Giacomo Gianfaldoni, Matteo Piccini, Leonardo Signori and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Niccolò BartalucciDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy. niccolo.bartalucci@unifi.it.ORCID 0000-0002-9328-3948
Francesco MannelliDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.ORCID 0000-0003-4810-6501
Danilo TarantinoDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.ORCID 0000-0003-0821-2051
Alessio EndertiDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Simone RomagnoliDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Daniele ColazzoDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Barbara ScappiniHematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Giacomo GianfaldoniHematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Matteo PicciniHematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Leonardo SignoriDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Fiorenza IrushaniDepartment of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.
Silvia SalmoiraghiFROM ResearchFoundation, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Tiziana OttoneDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0003-1936-3592
Alfonso PiciocchiGIMEMA Foundation, Rome, Italy.ORCID 0000-0001-8648-885X
Margherita VannucchiDepartment of Medical Biotechnology, Section of Pathology, University of Siena, Siena, Italy.
Maria Chiara SicilianoDepartment of Medical Biotechnology, Section of Pathology, University of Siena, Siena, Italy.
Roberto BoccacciDepartment of Medical Biotechnology, Section of Pathology, University of Siena, Siena, Italy.
Silvia OrsiDepartment of Medicine, University of Padova, Padova, Italy.
Alessia CiviniFROM ResearchFoundation, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Paola FaziGIMEMA Foundation, Rome, Italy.
Raffaella SantiDepartment of Health Sciences, Pathology Section, University of Florence, Florence, Italy.
Marco VignettiGIMEMA Foundation, Rome, Italy.ORCID 0000-0003-1278-604X
Stefania BortoluzziDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.ORCID 0000-0001-8240-3070
Alberto BosiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Adriano VendittiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0002-0245-0553
Alessandro RambaldiDepartment of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.ORCID 0000-0002-3739-7502
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0002-6164-4761
Paola Guglielmelli *Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy.ORCID 0000-0003-1809-284X
Alessandro M Vannucchi *Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy. a.vannucchi@unifi.it.ORCID 0000-0001-5755-0730

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytogenetic and genomic profiling of acute myeloid leukemia (AML) guides personalized treatment according to ELN2022 recommendations. However, marked outcome variability persists among cytogenetically normal (CN-) patients, representing an unmet clinical need. We used long-read whole-genome sequencing to interrogate the prognostic significance of structural variations (SVs) in a prospective cohort of 162 intensively treated CN-AML patients. After stringent filtering, we identified 5 somatic SVs associated with shorter overall survival (OS) (HR:4.18, p < 0.001) and event-free survival (EFS) (HR:3.59, p < 0.001) in 13% of the patients. Results were validated in a real-world cohort of 149 CN-AML, using target assays. These high-risk SVs (HRVs) operationally defined a "very high-risk" category in the framework of ELN2022, overall resulting in more accurate OS prediction. HRVs were independent of most frequent mutations, particularly FLT3

Indexed as

Genomic Structural VariationLeukemia, Myeloid, AcuteAdultAgedFemaleGenomicsHumansMaleMiddle AgedMutationNucleophosminPrognosisNPM1 protein, humanNucleophosmin

Identifiers

PMID41792115
PMCPMC13005009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.